Intercept Pharma

Intercept Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline includes OCALIVA, which is used for the treatment of biliary cholangitis, nonalcoholic steatohepatitis, sclerosing cholangitis and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in Morristown, NJ.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Intercept Pharma reports robust earnings, eyes growth amid competitive challenges

Intercept Pharma's Q4 2022 earnings call highlighted strong financial performance, strategic advancements, and a focus on innovation and market expansion.
The company's achievements in sales growth, patent protection, and financial stability position it well for future growth and leadership in the PBC and NASH markets.
Challenges in competitive dynamics and regulatory landscape require proactive strategies, while opportunities in new programs and market developments offer avenues for continued success.
Overall, Intercept Pharma's performance underscores a resilient and forward-thinking approach to navigating the complexities of the pharmaceutical industry and driving sustainable growth.

Intercept Pharma reports growth in sales and navigates NASH landscape

Intercept Pharma's Q1 2023 performance saw growth in net sales and strong sales performance of OCALIVA.
The company's focus on F3-like NASH patients and competitive positioning of OCA are key strengths.
Challenges include pricing strategy discussions and questions on combination approaches.
Opportunities lie in addressing AdCom discussions, expanding prescriber base, and preventing cirrhosis progression.

Intercept Pharma reports strong Q2 earnings, eyes FDA relations

Intercept Pharma's strong performance in Q2 2023 shows progress towards profitability by 2024. The company is addressing challenges in FDA relations and study enrollments while leveraging market opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Inovio Pharmaceuticals

Sarepta Therapeutics

Analysts believe these underperformers could nearly double over the next 12 months.

3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street

The company faced challenges last year in expanding the label of its only drug. Will 2021 bring different results?

With Important Trial Results Due in June, Is This Drugmaker a Good Buy Now?

Nikola

Plug Power

Skillz

Vaxart

Analysts' consensus price targets imply that these stocks can more than double over the next 12 months.

5 Stocks With 103% to 146% Upside, According to Wall Street

Fastly

Root

Hint: They're not AMC Entertainment, GameStop, or Sundial Growers.

3 Stocks Primed for a Short Squeeze

CrowdStrike

Kirkland Lake Gold

Bargains abound for growth seekers and value investors.

3 Top Stocks That'll Make You Richer in April (and Beyond)

Intercept (ICPT) reported earnings 30 days ago. What's next for the stock?

Intercept (ICPT) Up 0.4% Since Last Earnings Report: Can It Continue?

You've probably never heard about these fast-paced companies before, but Wall Street believes they can make you a boatload of money.

3 Under-the-Radar Growth Stocks With 55% to 106% Upside, According to Wall Street

Nordstrom

Nielsen Hlds

PayPal

Cardtronics

Cheniere Energy Partners

Kodiak Sciences Inc

MongoDB

StoneCo

With the trading day nearing halfway over, the broad markets were somewhat mixed to close out the week.

Nielsen, Nordstrom, PayPal and More Friday Afternoon Analyst Calls

NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Sandip Kapadia, Chief Financial Officer, will leave Intercept to pursue another opportunity. Mr. Kapadia will continue to serve as Chief Financial Officer until his departure on March 26, 2021. The Company also announced Mr. Rocco Venezia will be appointed Chief Accounting Officer and will serve as acting Chief Financial Officer until a permanent replacement is announced.

Intercept Announces Departure of Chief Financial Officer

Intercept (ICPT) posts a wider loss and misses on sales in the fourth quarter of 2020.

Intercept's (ICPT) Q4 Loss Wider than Expected, Sales Miss

Intercept Pharmaceuticals, Inc. (ICPT) CEO Jerry Durso on Q4 2020 Results - Earnings Call Transcript

Intercept (ICPT) delivered earnings and revenue surprises of -1.94% and -0.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Misses Revenue Estimates

Worldwide Ocaliva ® net sales of $83.3 million and $312.7 million for the fourth quarter and full year 2020, representing 18% and 25% growth over the prior year

Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results, Issues 2021 Financial Guidance and Provides Business Update

Kohl's

Spotify

Exxon Mobil

Foot Locker

Heineken NV

Medallia Inc

MGM Resorts

Okta

Ping Identity Holding Corp

With the trading day more than halfway over, the broad markets have pulled back from their recent all-time highs.

Exxon, Kohl's, MGM, Spotify and More Tuesday Afternoon Analyst Calls

NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Dagmar Rosa-Bjorkeson to its Board of Directors as of April 1, 2021.

Intercept Appoints Dagmar Rosa-Bjorkeson to Its Board of Directors

Lisa DeFrancesco, Senior Vice President, Corporate Affairs & Investor Relations, will join Intercept's Executive Leadership Team

Intercept Appoints Linda Richardson as Chief Commercial Officer

NEW YORK, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that an analyst note commenting on the listing of Intercept's product on the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) website reached a conclusion regarding the status of a newly identified safety signal (NISS) for Ocaliva® (obeticholic acid) that the Company believes is incorrect.

Intercept Company Statement on Analyst Note

Kinross Gold

These bounce-back plays might be diamonds in the rough.

3 Turnaround Stocks With 75% to 84% Upside, According to Wall Street

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of Jared M. Freedberg as General Counsel and Secretary. Mr. Freedberg joins Intercept from Immunomedics, Inc., which was acquired by Gilead Sciences in October of 2020.

Intercept Appoints Jared M. Freedberg as General Counsel and Secretary

Intercept has suffered an important set back with the FDA's CRL for Ocaliva in NASH with liver fibrosis. Ocaliva may still be approvable in NASH and the risk-reward for ICPT is more appealing at current levels.

Intercept Might Be An Intriguing Turn-Around Story

New York, New York--(Newsfile Corp. - January 4, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Intercept Pharmaceuticals, Inc. ("Intercept") (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To get more...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Intercept Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 4, 2021 - ICPT

New York, New York--(Newsfile Corp. - January 4, 2021) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between September 28, 2019 and October 7, 2020, inclusive (the "Class Period"), of the important January 4, 2021 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Intercept investors under the federal securities laws.To join the Intercept class action,...

ICPT Final Deadline Today: Rosen, National Trial Lawyers, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm - ICPT

LOS ANGELES, Jan. 4, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ: ICPT) for violations of §§10(b) and 20(a) of the...

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Intercept Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Boston Scientific

Northern Dynasty Minerals

NEW YORK, NY / ACCESSWIRE / January 3, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court.

CLASS ACTION UPDATE for ICPT, BSX and NAK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Intercept Pharmaceuticals, Inc. ("Intercept" or "the Company") (NASDAQ: ICPT) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Intercept securities between September 28, 2019 and October 7, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.b

ICPT Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Intercept Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: January 4, 2021

News for Intercept Pharma Stock (ICPT)